Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking people18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 200
- Run by
- Peking University First Hospital
See details and how to joinNCT07557225 - Phase 2Taking peopleFOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
- Where
- Tianjin
- Age
- 18 years and over
- People
- 30
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07012798 - Phase 1Not yet taking people in ChinaA Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 192
- Run by
- Corregene Biotechnology Co., Ltd
See details and how to joinNCT07583316 - Phase 2Taking peopleTislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years and over
- People
- 94
- Run by
- Tongji Hospital
See details and how to joinNCT07413354 - Phase 1Not yet taking people in ChinaYMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- Where
- Chengdu
- Age
- 18 years to 70 years
- People
- 10
- Run by
- West China Hospital
See details and how to joinNCT07580261 - No phaseNot yet taking people in ChinaHybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
- Where
- Changchun
- Age
- 18 years to 85 years
- People
- 1,424
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07582419 - No phaseTaking peopleEfficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 17
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06794073 - Phase 4Taking peopleThe Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
- Where
- Hefei
- Age
- 18 years to 70 years
- People
- 96
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07150624 - No phaseTaking peopleHAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Peking University
See details and how to joinNCT07466238 - Phase 2Taking peopleAlternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
- Where
- Xi'an
- Age
- 18 years and over
- People
- 124
- Run by
- Air Force Military Medical University, China
See details and how to joinNCT07569679 - Phase 2Taking peopleChidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07570849 - Phase 2Taking peopleNeoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 33
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07014150 - Phase 2Not yet taking people in ChinaNanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 88
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07565415 - Phase 3Taking peopleDEB-TACE vs cTACE in HCC After TIPS
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 206
- Run by
- First Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07322848 - Phase 1Taking peopleA Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- Where
- Fuzhou, Nanning
- Age
- 18 years and over
- People
- 36
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07478302 - Phase 2Taking peopleIpilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 43
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07560488 - Phase 1Not yet taking people in ChinaPhase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 138
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07558200 - Early phase 1Not yet taking people in ChinaEfficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
- Where
- Hangzhou, Ningbo
- Age
- 18 years to 65 years
- People
- 156
- Run by
- Ningbo No.2 Hospital
See details and how to joinNCT07553767 - Phase 2Taking peopleA Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07422753 - Phase 2Taking peopleHAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
- Where
- Shanghai
- Age
- 18 years and over
- People
- 164
- Run by
- Fudan University
See details and how to joinNCT06860490 - No phaseTaking peopleDifferent First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
- Where
- Shanghai
- Age
- 18 years and over
- People
- 150
- Run by
- Fudan University
See details and how to joinNCT07147101 - Phase 2Taking peopleA Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 350
- Run by
- Fudan University
See details and how to joinNCT07328009 - Early phase 1Not yet taking people in ChinaSafety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
- Where
- Hangzhou
- Age
- 19 years to 75 years
- People
- 27
- Run by
- Zhejiang University
See details and how to joinNCT07487402 - Phase 2Taking peopleBecotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 40
- Run by
- Fudan University
See details and how to joinNCT07536789 - No phaseTaking peopleAI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 108
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07538882